NeoGenomics Laboratories Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
2,100
- Stock Symbol
-
NEO
- Investments
-
8
- Share Price
-
$16.16
- (As of Wednesday Closing)
NeoGenomics Laboratories General Information
Description
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Contact Information
Website
www.neogenomics.comCorporate Office
- 9490 NeoGenomics Way
- Fort Myers, FL 33912
- United States
Corporate Office
- 9490 NeoGenomics Way
- Fort Myers, FL 33912
- United States
NeoGenomics Laboratories Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.16 | $16.29 | $11.03 - $21.22 | $2.07B | 128M | 726K | -$0.62 |
NeoGenomics Laboratories Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,994,717 | 2,265,832 | 1,335,079 | 4,271,048 |
| Revenue | 628,248 | 591,643 | 509,728 | 484,329 |
| EBITDA | (22,646) | (34,509) | (88,406) | 43,359 |
| Net Income | (78,545) | (87,968) | (144,250) | (8,347) |
| Total Assets | 1,643,277 | 1,681,229 | 1,740,034 | 1,869,778 |
| Total Debt | 606,518 | 611,679 | 610,928 | 612,791 |
NeoGenomics Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NeoGenomics Laboratories Comparisons
Industry
Financing
Details
00000
000000
NeoGenomics Laboratories Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quest Diagnostics | Corporation | Secaucus, NJ | 00000 | 00.000 | 000000000 - | 00.000 |
| PathGroup | Private Equity-Backed | Brentwood, TN | 000 | 0000 | 000000000000 | 0000 |
| Dahl-Chase Diagnostic Services | Private Equity-Backed | Bangor, ME | 00 | 000000000000 | ||
| Laboratory Corporation of America | Private Debt Financed | Burlington, NC | 00000 | 00.000 | 000000000000 | 00.000 |
| Blueprint Genetics | Formerly VC-backed | Espoo, Finland | 000 | 000.00 | 000000&0 | 000.00 |
NeoGenomics Laboratories Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeoGenomics Laboratories Patents
NeoGenomics Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4320442-A1 | Perivascular accumulation of immune cells in the diagnosis and treatment of cancer | Pending | 09-Apr-2021 | 000000000000 | |
| US-20240241128-A1 | Perivascular accumulation of immune cells in the diagnosis and treatment of cancer | Pending | 09-Apr-2021 | 000000000000 | |
| US-10253370-B2 | High-sensitivity sequencing to detect btk inhibitor resistance | Inactive | 17-Aug-2015 | 0000000000 | 0 |
| US-20170051357-A1 | High-sensitivity sequencing to detect btk inhibitor resistance | Active | 17-Aug-2015 | 0000000000 | |
| US-20170002427-A1 | Method for high sensitivity detection of myd88 mutations | Active | 01-Jul-2015 | C12Q1/6886 |
NeoGenomics Laboratories Executive Team (36)
| Name | Title | Board Seat |
|---|---|---|
| Melody Harris JD | Chief Operating Officer, Operations & President | |
| Cynthia Dieter | Chief Accounting Officer, Accounting & Controller, Finance | |
| Gregory Aunan | Chief Accounting Officer, Accounting | |
| Gary Passman | Chief Culture Officer | |
| Warren Stone | Executive |
NeoGenomics Laboratories Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 000000 | Self | Board Member | 000 0000 |
| 00000 00000000 | Self | Board Member | 000 0000 |
| 00000000000 00000 | Self | Chief Executive Officer & Board Member | 000 0000 |
| 0000 00000000 00 | Self | Chair of the Board | 000 0000 |
| 0000000 00000000 | Self | Board Member | 000 0000 |
NeoGenomics Laboratories Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
NeoGenomics Laboratories Investments & Acquisitions (8)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Inivata | 18-Jun-2021 | 0000000000 | 00000 | Diagnostic Equipment | 0000 0000 |
| Trapelo Health | 07-Apr-2021 | 0000000000 | 000.00 | Other Healthcare Technology Systems | 0000000 0 |
| Inivata | 03-Jun-2020 | 00000 0000 | 000.00 | Diagnostic Equipment | 0000000 0 |
| Human Longevity (Oncology Division) | 10-Jan-2020 | 0000000000 | 0000 | Drug Discovery | 0000000 0 |
| NeoGenomics Laboratories (NGS Lab in La Jolla, California) | 01-Jan-2020 | Corporate Asset Purchase | Buildings and Property |
NeoGenomics Laboratories Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Inivata | Diagnostic Equipment | Cambridge, United Kingdom | 2014 |
| Trapelo Health | Other Healthcare Technology Systems | Fort Myers, FL | 0000 |
| Clarient | Laboratory Services (Healthcare) | Aliso Viejo, CA | 0000 |
NeoGenomics Laboratories ESG
Risk Overview
Risk Rating
Updated December, 30, 2023
19.97 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Laboratory Equipment and Services
Subindustry
00 of 59
Rank
Percentile
NeoGenomics Laboratories FAQs
-
When was NeoGenomics Laboratories founded?
NeoGenomics Laboratories was founded in 1998.
-
Who is the CEO of NeoGenomics Laboratories?
Christopher Smith is the CEO of NeoGenomics Laboratories.
-
Where is NeoGenomics Laboratories headquartered?
NeoGenomics Laboratories is headquartered in Fort Myers, FL.
-
What is the size of NeoGenomics Laboratories?
NeoGenomics Laboratories has 2,100 total employees.
-
What industry is NeoGenomics Laboratories in?
NeoGenomics Laboratories’s primary industry is Laboratory Services (Healthcare).
-
Is NeoGenomics Laboratories a private or public company?
NeoGenomics Laboratories is a Public company.
-
What is NeoGenomics Laboratories’s stock symbol?
The ticker symbol for NeoGenomics Laboratories is NEO.
-
What is the current stock price of NeoGenomics Laboratories?
As of 18-Sep-2024 the stock price of NeoGenomics Laboratories is $16.16.
-
What is the current market cap of NeoGenomics Laboratories?
The current market capitalization of NeoGenomics Laboratories is $2.07B.
-
What is NeoGenomics Laboratories’s current revenue?
The trailing twelve month revenue for NeoGenomics Laboratories is $628M.
-
Who are NeoGenomics Laboratories’s competitors?
Quest Diagnostics, PathGroup, Dahl-Chase Diagnostic Services, Laboratory Corporation of America, and Blueprint Genetics are some of the 13 competitors of NeoGenomics Laboratories.
-
What is NeoGenomics Laboratories’s annual earnings per share (EPS)?
NeoGenomics Laboratories’s EPS for 12 months was -$0.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
